Results 1 to 10 of about 73,612 (157)

Effectiveness of tacrolimus therapy in refractory ulcerative colitis compared to infliximab with propensity score matching [PDF]

Scientific Reports
There is insufficient evidence comparing the outcomes of tacrolimus-based remission induction therapy with infliximab in refractory ulcerative colitis (UC) and evidence regarding optimal strategies after tacrolimus-based remission induction therapy.
Takeo Yoshihara, Takahiro Amano, Shinichiro Shinzaki, Yuri Tsujii, Akiko Asakura, Taku Tashiro, Mizuki Tani, Yuriko Otake-Kasamoto, Takuya Yamada, Yuko Sakakibara, Naoto Osugi, Shuji Ishii, Satoshi Egawa, Manabu Araki, Yuki Arimoto, Masanori Nakahara, Yoko Murayama, Ichizo Kobayashi, Kazuo Kinoshita, Hiroyuki Ogawa, Satoshi Hiyama, Narihiro Shibukawa, Masato Komori, Yorihide Okuda, Takashi Kizu, Tetsuhisa Kitamura, Minoru Kato, Yoshiki Tsujii, Takahiro Inoue, Hideki Iijima, Yoshito Hayashi, Tetsuo Takehara   +31 more
doaj   +2 more sources

Human kidney organoids model the tacrolimus nephrotoxicity and elucidate the role of autophagy [PDF]

The Korean Journal of Internal Medicine, 2021
Background/Aims Tacrolimus has been used as an immunosuppressive agent in organ transplantation. Despite the therapeutic benefits, tacrolimus’s use is limited due to its nephrotoxicity.
Jin Won Kim, Sun Ah Nam, Eunjeong Seo, Jong Young Lee, Dohui Kim, Ji Hyeon Ju, Sun Woo Lim, Hong Lim Kim, Hyung Wook Kim, Chul Woo Yang, Jin Kim, Dong Sung Kim, Yong Kyun Kim   +12 more
doaj   +1 more source

Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation

Frontiers in Pharmacology, 2021
Background and Purpose: Several formulations of tacrolimus are available, but evidence of the benefit of changing to the most recent formulations is lacking. Tacrolimus intra-patient variability (tacrolimus IPV) is an emerging risk factor associated with
Arnaud Del Bello, Arnaud Del Bello, Arnaud Del Bello, Clotilde Gaible, Nathalie Longlune, Anne-Laure Hebral, Laure Esposito, Peggy Gandia, Peggy Gandia, Nassim Kamar, Nassim Kamar, Nassim Kamar   +11 more
doaj   +1 more source

A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients

Clinical and Translational Science, 2022
A high intrapatient variability (IPV) in tacrolimus exposure is a risk factor for poor long‐term outcomes after kidney transplantation. The main objective of this trial was to investigate whether tacrolimus IPV decreases after switching patients from ...
Kim L. W. Bunthof, Linda Al‐Hassany, Gizal Nakshbandi, Dennis A. Hesselink, Ron H. N. vanSchaik, Marc A. G. J. ten Dam, Marije C. Baas, Luuk B. Hilbrands, Teun vanGelder   +8 more
doaj   +1 more source

Tacrolimus monitoring in hair samples of kidney transplant recipients

Frontiers in Medicine, 2023
BackgroundCalcineurin inhibitors, including tacrolimus, remain a cornerstone of immunosuppressive therapy after kidney transplantation. However, the therapeutic window is narrow, and nephrotoxic side effects occur with overdose, while the risk of ...
Alexander Born, Federica Bocchi, Christian Kuhn, Ursula Amstutz, Markus R. Baumgartner, Daniel Sidler   +5 more
doaj   +1 more source

Can We Predict Individual Concentrations of Tacrolimus After Liver Transplantation? Application and Tweaking of a Published Population Pharmacokinetic Model in Clinical Practice [PDF]

Therapeutic Drug Monitoring, 2021, 43 (4), pp.490-498, 2023
Background: Various population pharmacokinetic models have been developed to describe the pharmacokinetics of tacrolimus in adult liver transplantation. However, their extrapolated predictive performance remains unclear in clinical practice. The purpose of this study was to predict concentrations using a selected literature model and to improve these ...
arxiv   +1 more source

Tacrolimus-induced neurotoxicity from bipolar disorder to status epilepticus under the therapeutic serum level: a case report

BMC Neurology, 2021
Background Tacrolimus is a macrolide immunosuppressant widely used to prevent rejection after solid organ transplantation. In general, adverse events of tacrolimus occur more often as the concentration of tacrolimus in the blood increases.
Bora Jin, Ga Yeon Kim, Sang-Myung Cheon
doaj   +1 more source

Clinical association between tacrolimus intra-patient variability and liver transplantation outcomes in patients with and without hepatocellular carcinoma

Scientific Reports, 2022
Tacrolimus is the mainstay of immunosuppression in liver transplantation to prevent rejection. However, the clinical use of tacrolimus is complicated by its narrow therapeutic window and significant intra-patient variability (IPV). High tacrolimus IPV is
Hyun Jeong Kim, Juhan Lee, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim   +4 more
doaj   +1 more source

Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus

BMC Gastroenterology, 2021
Background Intravenous corticosteroid is the mainstay for managing acute severe ulcerative colitis, but one-third of patients do not respond to intravenous corticosteroid.
Hiromichi Shimizu, Toshimitsu Fujii, Kenji Kinoshita, Ami Kawamoto, Shuji Hibiya, Kento Takenaka, Eiko Saito, Masakazu Nagahori, Kazuo Ohtsuka, Mamoru Watanabe, Ryuichi Okamoto   +10 more
doaj   +1 more source

Efficacy and safety of a switch from twice-daily tacrolimus to once-daily generic tacrolimus in stable liver transplant patients

Korean Journal of Transplantation, 2021
Background : Once-daily tacrolimus reduces non-compliance relative to twice-daily tacrolimus. However, little is known about the safety and efficacy of conversion from twice-daily tacrolimus to generic once-daily tacrolimus in liver transplantation (LT).
Jong Man Kim, Pyoung-Jae Park, Geun Hong, Dong Jin Joo, Kwan Woo Kim, Je Ho Ryu, Young Seok Han, Jai Young Cho, Gi-Won Song, Bong-Wan Kim, Dong-Sik Kim, Seong Hoon Kim, Sang Tae Choi, Young Kyoung You, Kyung-Suk Suh, Yang-Won Na, Koo Jeong Kang, Jae-Won Joh   +17 more
doaj   +1 more source